Tracer library / [177Lu]Lu-PP-F11N
[177Lu]Lu-PP-F11N
Also written as [Lu-177]Lu-PP-F11N; PP-F11N; Lu-177-PP-F11N
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 3
What it is
- Compound class
- Radiolabeled minigastrin analogue (CCK2/CCKB receptor-targeting peptide, DOTA-conjugated)
- Target / mechanism
- Cholecystokinin-2 receptor (CCK2R/CCKBR) agonist PMID 31519804
- Clinical application
- Targeted radionuclide therapy of CCK2R-positive medullary thyroid carcinoma PMID 31519804
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | >95% | PP-F11N | 34071914 2021 Cancers (Basel) |
| Manual synthesis | — | HPLC | — | >99% | DOTA-PP-F11N PSL GmbH, Heidelberg, Germany | 33198403 2020 Pharmaceutics The labeling was carried out at 90 °C for 15 min. |
| Manual synthesis | — | HPLC | — | >95% | PP-F11N…PP-F11N (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2) PSL GmbH, Heidelberg, Germany | 33042258 2020 Theranostics The labeling reaction contained 1:30 nuclide/peptide ratio in 0.4 M ammonium acetate buffer (pH 5.5) and was carried out at 90 °C for 15 min. |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study.2024 · EJNMMI Res · Prospective · Phase 0
- Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.2020 · J Nucl Med · Clinical study · Phase 0
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- PSL GmbH
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-PP-F11N, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 6 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38581480: 'In this prospective phase 0 study eight consecutive patients with advanced medullary thyroid carcinoma and a current somatostatin receptor subtype 2 PET/CT scan were included.'. | Stage 30 (2026-09-18): Stage was 'clinical trial (phase 0)'; normalised to 'Clinical research', original wording kept here.